Literature DB >> 16829339

Peripheral nerve functions may deteriorate parallel to the progression of microangiopathy in diabetic patients.

Kenichi Ogawa1, Hideyuki Sasaki, Hiroshi Yamasaki, Kunihisa Okamoto, Shohei Matsuno, Takeshi Shono, Takuya Doi, Keiko Arimoto, Hiroto Furuta, Masahiro Nishi, Taisei Nakao, Kishio Nanjo.   

Abstract

Our aim was to obtain information to help in the early detection of impaired nerve function and to assess the severity of diabetic symmetric polyneuropathy (DPN). Various somatic and autonomic nerve functions in 40 diabetics and 20 age-matched healthy volunteers were evaluated using six objective examinations: nerve conduction study, quantitative vibratory perception threshold, heart rate variability, Valsalva test, head-up tilt and quantitative sudomotor axonal reflex test (QSART). The diabetics were divided into three groups according to the severity of their microangiopathy. The nerve function data and level of impairment were compared between a healthy control and three diabetic groups. The relationships between nerve function data and clinical background were also examined using multivariate analysis. Results were as follows: (1) all nerve dysfunctions seemed to develop parallel to the progression of microangiopathy, (2) reduced nerve conduction velocity and elevated vibratory perception thresholds in the feet might be early detectable signs of DPN, (3) vasomotor and sudomotor sympathetic functions and cardiovagal functions seemed to deteriorate with the appearance of microangiopathy, (4) lowered compound muscle action potential seemed to appear at the advanced microangiopathic condition, (5) hypohydrosis was closely related to diabetic foot ulcers. In conclusion, nerve dysfunction in diabetics might generally progress with microangiopathy from somatic sensory nerve dysfunction to autonomic nerve dysfunction and then to somatic motor nerve dysfunction. Sympathetic sudomotor dysfunction might be a sensitive predictor of diabetic foot ulcer.

Entities:  

Mesh:

Year:  2005        PMID: 16829339     DOI: 10.1016/j.numecd.2005.06.003

Source DB:  PubMed          Journal:  Nutr Metab Cardiovasc Dis        ISSN: 0939-4753            Impact factor:   4.222


  5 in total

1.  Diabetic Peripheral Neuropathy Increases Electrical Stimulation Threshold of Sciatic Nerve: A Prospective Parallel Cohort Study.

Authors:  Guang Ying Zhang; Yi Feng Chen; Wei Xin Dai; Dan Zhang; Yi Huang; Wen Zheng He; Cheng Xin Lin
Journal:  Diabetes Metab Syndr Obes       Date:  2020-11-18       Impact factor: 3.168

2.  Insulin-ameliorated peripheral motor neuropathy in spontaneously diabetic WBN/Kob rats.

Authors:  Kiyokazu Ozaki; Shotaro Yamano; Tetsuro Matsuura; Isao Narama
Journal:  J Vet Med Sci       Date:  2013-07-07       Impact factor: 1.267

3.  Pro198Leu missense polymorphism of the glutathione peroxidase 1 gene might be a common genetic predisposition of distal symmetric polyneuropathy and macrovascular disease in Japanese type 2 diabetic patients.

Authors:  Shohei Matsuno; Hideyuki Sasaki; Hiroshi Yamasaki; Hiroyuki Yamaoka; Kenichi Ogawa; Muneki Nakatani; Tohru Hamanishi; Asako Doi; Yoshio Nakano; Hisao Wakasaki; Hiroto Furuta; Masahiro Nishi; Takashi Akamizu; Kishio Nanjo
Journal:  J Diabetes Investig       Date:  2011-11-30       Impact factor: 4.232

4.  Relationship between sonographically measured median nerve cross-sectional area and presence of peripheral neuropathy in diabetic subjects.

Authors:  Fredrick Andrew Attah; Christianah Mopelola Asaleye; Adeleye Dorcas Omisore; Babatope Ayodeji Kolawole; Adeniyi Sunday Aderibigbe; Mathew Alo
Journal:  World J Diabetes       Date:  2019-01-15

5.  Association Between Severity of Diabetic Neuropathy and Success in Weight Loss During Hospitalization Among Japanese Patients with Type 2 Diabetes: A Retrospective Observational Study.

Authors:  Shuhei Nakanishi; Hidenori Hirukawa; Masashi Shimoda; Fuminori Tatsumi; Kenji Kohara; Atsushi Obata; Seizo Okauchi; Junpei Sanada; Yoshiro Fushimi; Akiko Mashiko; Tomoatsu Mune; Kohei Kaku; Hideaki Kaneto
Journal:  Diabetes Metab Syndr Obes       Date:  2020-05-15       Impact factor: 3.168

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.